Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. Barnes, A. Mansur, A. Menzies-Gow, A. Radwan, on behalf of the APEX study investigators (London, Birmingham, Frimley/Camberley, United Kingdom). The APEX study: A retrospective review of outcomes in patients with severe allergic asthma who were or were not hospitalised in the year prior to omalizumab initiation in UK clinical practice. Eur Respir J 2012; 40: Suppl. 56, 2338

Member's Comments

No comment yet.

Related content which might interest you: The APEX study: Retrospective review of oral corticosteroid use in omalizumab-treated severe allergic asthma patients in UK clinical practice Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011 The APEX study: A retrospective review of responses of severe allergic asthma patients to omalizumab on continuous or non-continuous oral corticosteroids in UK clinical practice Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011 Effectiveness of omalizumab in Canadian patients with allergic asthma: A retrospective study. Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Analysis of two-year treatment with omalizumab patients with severe asthma in real clinical practice Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Real-life effectiveness of omalizumab in difficult-to-treat versus severe asthma: a national cohort study in Belgium Source: ERJ Open Res, 5 (4) 00253-2018; 10.1183/23120541.00253-2018 Year: 2019 Neomacrolides in the treatment of patients with severe asthma and/or bronchiectasis: A retrospective observational study Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010 Stop omalizumab: a multicenter follow up study after discontinuation in pediatric patients with severe asthma Source: Virtual Congress 2021 – Paediatric allergic asthma: novel therapeutics and monitoring approaches Year: 2021 Omalizumab reduces asthma exacerbations and oral corticosteroid use in patients with severe allergic asthma: a systematic review of observational studies Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019 Dispensed asthma therapy and medical resource utilisation in asthma patients: results from the L777 observational study Source: Annual Congress 2009 - Epidemiology of asthma Year: 2009 Analysis of pre-hospital management in hospitalized patients with bronchial asthma (BA) exacerbation: 6-year observational study Source: Eur Respir J 2006; 28: Suppl. 50, 313s Year: 2006 Real life study showing the epidemiological profile and adherence to treatment of patients with severe allergic asthma in use of omalizumab in the past year. Source: International Congress 2018 – Biomarkers for evaluating asthma Year: 2018 Omalizumab exposure patterns in real-life: An 11-year French population-based study of 19,203 patients with severe asthma. Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 The Spanish national clinical audit on COPD exacerbations. results of a pilot study: spirometry outcomes Source: Annual Congress 2008 - Organisation of care and management of COPD Year: 2008 Utility of adherence checks in patients with severe asthma eligible for biologics: a single centre retrospective analysis Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Impact of subcutaneous allergoid AIT on patients with allergic rhinitis and/or asthma: A retrospective real-life, long-term cohort analysis Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020 Characteristics of asthma patients with frequent exacerbations – an observational study in Sweden Source: International Congress 2017 – Primary care management of asthma and self-management of respiratory disease Year: 2017 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 ‘Real-life‘ persistence beyond the first year of omalizumab treatment in patients with severe allergic asthma: The R-Pixel study Source: Annual Congress 2011 - Asthma management and response Year: 2011 Interim analysis of a prospective study investigating oral corticosteroid (OCS) use in omalizumab treated severe allergic asthma patients: APEX II study Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Effect of omalizumab on the risk of hospitalisation in patients with uncontrolled severe asthma in real-life. The PAX-LASER cohort Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010